Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Jefferies London Healthcare Conference 2022
16 slides from Neuren Pharmaceuticals's conference presentation, Nov 18, 2022
Slide 1: Improving the lives of people with neurodevelopmental disabilities
For personal use only IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES 17 November 2022 Jefferies London Healthcare Conference 2022
Slide 2: Forward looking statements
Forward looking statements For personal use only This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expe
Slide 3: Highlights
Highlights For personal use only 1 2 3 Potential revenue from Acadia in NDA for trofinetide to treat Rett 2023 for Rett syndrome in the US Strong partnering interest syndrome accepted by FDA for alone of US$73m (A$112 received for trofinetide outside Priority Review with PDUFA date million)1 plus do
Slide 4: Seeking a ground-breaking impact on neurodevelopmental disorders
Seeking a ground-breaking impact on neurodevelopmental disorders For personal use only Rett Fragile X Phelan- Angelman Pitt Hopkins Prader-Willi McDermid MECP2 FMR1 SHANK3 UBE3A TCF4 15q11-q13 Neuren’s drugs target the Impaired communication between critical role of IGF-1 in this neurons, abnormal f
Slide 5: All development programs at Phase 2 or later
All development programs at Phase 2 or later For personal use only Commercial Compound Indication Preclinical Phase 1 Phase 2 Phase 3 Registration rights US PDUFA Rett2 date 12 Mar 20231 NA: Trofinetide RoW: Fragile X2 Phelan- McDermid3 Angelman3 Results H1 2023 NNZ-2591 Pitt Hopkins3 Prader-Willi4
Slide 6: Attractiveness of Orphan Drug model
Attractiveness of Orphan Drug model For personal use only Neuren is targeting multiple “rare diseases”, but they are not “ultra-rare” Marketing exclusivity periods protect against generics independent of patents (7.5 years in US, 12 years in EU, 10 years in Japan, South Korea and 1 Taiwan, China h
Slide 7: Three key drivers transforming near term value
Three key drivers transforming near term value For personal use only Realise Neuren’s Implement share of trofinetide commercial strategy Confirm efficacy of value in the US for trofinetide ex- NNZ-2591 in Phase 2 through Acadia’s New North America, using trials for 4 valuable Drug Application for US
Slide 8: Rett syndrome Phase 3 and NDA
Rett syndrome Phase 3 and NDA For personal use only Acadia submitted NDA in July 2022 for treatment of Rett syndrome in patients two years of age and older NDA based on pivotal efficacy from positive Phase 3 trial, supportive efficacy from Neuren’s positive Phase 2 trial, safety data from comple
Slide 9: Rett commercial opportunity largely de-risked
Rett commercial opportunity largely de-risked For personal use only Estimates US Europe Japan China urban Other Asia Potential patients1 10,000 13,000 3,000 28,000 6,000 Patients currently identified 5,000 4,000 1,000 2,000 ‘00s North America Ex-North America Neuren potential revenue from Acadia:
Slide 10: 5x larger opportunity for NNZ-2591
5x larger opportunity for NNZ-2591 For personal use only Disorder Gene Published prevalence estimates Potential patients mutation US1 Europe1 Asia1, 2 Phelan- SHANK3 1/8,000 to 1/15,000 males and females 22,000 28,000 81,000 McDermid Angelman UBE3A 1/12,000 to 1/24,000 males and 14,000 18,000 52,000
Slide 11: NNZ-2591 has ideal attributes leading into Phase 2
NNZ-2591 has ideal attributes leading into Phase 2 For personal use only Novel mechanism of action Clear and consistent efficacy in mouse models of each syndrome Biochemical effects in the brain confirmed Optimum dose identified Demonstrated high oral bioavailability and blood-brain barrie
Slide 12: Clear and consistent efficacy in animal models
Clear and consistent efficacy in animal models For personal use only Memory Learning Sociability Motor function Anxiety Repetitive behavior Daily living Daily living Incidence of seizures WT + vehicle 0% KO + vehicle 60% Phelan- KO + x mg/kg 50% McDermid KO + 2x mg/kg 30% KO + 4x mg/kg 10% KO + 8x m
Slide 13: Biochemical effects confirmed
Biochemical effects confirmed For personal use only In biochemical testing, NNZ-2591 was shown to normalise the abnormal length of dendrite spines between brain cells, the excess activated ERK protein (pERK) and the depressed level of IGF-1 in shank3 knockout mice 2000 4 16000 Dendritic length (m)
Slide 14: Key features of first Phase 2 trials
Key features of first Phase 2 trials For personal use only Overall aim – expedite data that enables subsequent trials to be designed as registration trials and prepare for Phase 3 in parallel Angelman Phelan-McDermid Pitt Hopkins Prioritising speed to data n subjects Up to 20 Up to 20 Up to 20 M
Slide 15: On track to deliver significant value upside over next months
On track to deliver significant value upside over next 18 months For personal use only Prader-Willi syndrome Phase 2 trial results (H2 2023) Phase 2 trial results in Angelman, Phelan-McDermid and Pitt Hopkins syndromes (H1 2023) Approval of NDA for Rett syndrome (Q1 2023) Commercial partnerships ex-
Slide 16: Contact
For personal use only CONTACT Jon Pilcher, CEO [email protected] +61 438 422 271 16
Neuren Pharmaceuticals — Jefferies London Healthcare Conference 2022 on 6ix